Cycle Pharmaceuticals

Cycle Pharmaceuticals company information, Employees & Contact Information

We’re committed to supporting patients and their caregivers in every way we can. They are at the heart of everything we do. We focus on providing treatments and services for patients with neurological, rare metabolic, and rare immunological conditions, most of which are genetic conditions. We’re headquartered in Cambridge, UK and have staff working across the US, with an office in Boston, MA.

Company Details

Employees
172
Founded
-
Address
The Broers Building,
Phone
+44 1223 354118
Email
in****@****rma.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Cambridge, Cambridgeshire
Looking for a particular Cycle Pharmaceuticals employee's phone or email?

Cycle Pharmaceuticals Questions

News

Cycle Pharmaceuticals Signs Exclusive U.S. Sales License for PHYRAGO™ (dasatinib) Tablets - Business Wire

Cycle Pharmaceuticals Signs Exclusive U.S. Sales License for PHYRAGO™ (dasatinib) Tablets Business Wire

Cycle Pharma Acquires Banner Life Sciences, LLC - Business Wire

Cycle Pharma Acquires Banner Life Sciences, LLC Business Wire

Cycle Pharmaceuticals - The Times

Cycle Pharmaceuticals The Times

Cycle Pharmaceuticals Selects LeMed Specialty Pharmacy as Exclusive U.S. Specialty Pharmacy Distribution and Services Partner for HARLIKU™ (nitisinone) Tablets --the First and only FDA-approved Treatment for Reducing Urinary Homogentisic Acid (HG - PR Newswire

Cycle Pharmaceuticals Selects LeMed Specialty Pharmacy as Exclusive U.S. Specialty Pharmacy Distribution and Services Partner for HARLIKU™ (nitisinone) Tablets --the First and only FDA-approved Treatment for Reducing Urinary Homogentisic Acid (HG PR Newswire

Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US - Yahoo Finance

Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US Yahoo Finance

FDA Approves Longer Shelf Life for Nityr Tablets - Medical Professionals Reference

FDA Approves Longer Shelf Life for Nityr Tablets Medical Professionals Reference

Cycle Pharmaceuticals launches HARLIKU™ (nitisinone) Tablets, the first FDA-approved treatment for use in Alkaptonuria (AKU) - Business Wire

Cycle Pharmaceuticals launches HARLIKU™ (nitisinone) Tablets, the first FDA-approved treatment for use in Alkaptonuria (AKU) Business Wire

Cycle Pharmaceuticals’ HARLIKU™ (nitisinone) Tablets Receive First FDA-Approval as Treatment for Alkaptonuria (AKU) - Business Wire

Cycle Pharmaceuticals’ HARLIKU™ (nitisinone) Tablets Receive First FDA-Approval as Treatment for Alkaptonuria (AKU) Business Wire

Cycle Pharmaceuticals Launches Cycle Vita , a Dedicated Support Platform for Rare Disease Patients - Business Wire

Cycle Pharmaceuticals Launches Cycle Vita , a Dedicated Support Platform for Rare Disease Patients Business Wire

Cycle Pharmaceuticals Secures $25 Million Debt Financing - Business Wire

Cycle Pharmaceuticals Secures $25 Million Debt Financing Business Wire

US FDA Grants Once Daily Dosing Option for NITYR (nitisinone) Tablets for HT-1 Patients - Business Wire

US FDA Grants Once Daily Dosing Option for NITYR (nitisinone) Tablets for HT-1 Patients Business Wire

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant